Nasdaq Biotechnology Ishares ETF (IBB)
$147.44
0.94 (0.64%)
IBB Stock Quote Delayed 30 Minutes
3 Biotech Stocks to Buy As Things Heat Up for the Sector
Biotech stocks offer a textbook retracement pattern. The risk is low, and the reward is high. Here's how to play it.
Louis Navellier's Top 6 Stocks for 2021
He found Apple at $1.49… Intel at $3.60... Amazon at $46. Now, investing legend Louis Navellier is revealing his Top 6 Stocks for 2021 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
12.82B
PE Ratio
-
EPS
-
Volume (Avg. Vol.)
1,913
Day's Range
146.50 - 146.50
52-Week Range
112.62 - 174.04
Dividend & Yield
0.31 (0.21%)
IBB Stock Predictions, Articles, and Nasdaq Biotechnology Ishares ETF News
A New Healthcare Stock Pick in the Industry of the Decade
This company is riding a powerful trend in the future of healthcare. Plus, it offers high growth, a huge potential market and a path to profitability.
Biotech Stocks Have Been on Fire, But Timing Is Everything
Consensus is that the experts will find a vaccine to Covid-19 soon, so the biotech stocks have rallied hard. Buying them now carries risk.
Biotech Stocks: Coronavirus Response Shows How Far We’ve Come …
Look for biotech stocks as a group to gain more than 20% this year … with the best, most innovative firms more than doubling.
First-Mover Advantage Will Benefit Amarin Stock More Than You Think
There’s no reason Amarin stock won’t become a big success with Vascepa, especially with access to millions of patients.
The Top Performing Sector in 2020 Will Be …
The future of healthcare will really start to take shape this year, and the next decade will bring advancements that we can only imagine in our wildest dreams.
3 of the Best Biotech ETFs on the Market
The fourth quarter has been a different story. IBB, the largest biotech ETF by assets, is up 16.65% since Oct. 1, pushing its year-to-date gain to 26.57% as of Dec. 20. That after months of investors pulling money from actively managed biotech funds, but that situation is starting to correct as well as data out this month indicate investors are warming to biotech assets again.
Why We Had to Add This Stock to Our 2020 “Screaming Buy” List
Our research and analysis have identified another name in biotech stocks with big potential in 2020.
You Can’t Afford to Miss This Buying Opportunity
There's a catalyst on the horizon that could send biotech stocks soaring into the stratosphere.
4 Top Stock Trades for Friday: MU, Biotech, Bitcoin
Bitcoin, Biotech, Micron and Starbucks were our top stock trades to watch. Here's how the charts are setting up going into Friday.
7 Biotech ETFs That Should Remain Healthy
The healthcare sector has been the worst performing on the S&P 500 in 2019, but these biotech ETFs are still worth a look.
Why Bristol-Myers Squibb Stock Is Stumbling Ahead of Earnings
Investors turned sour on BMY stock after the Celgene buyout. Will a solid Q2 earnings report change the sentiment for the better?
Nasdaq Today: iQiyi Surges on Award; Intel, Cisco Struggle
Memory stocks like Micron and semiconductor stocks like AMD were on the move in the Nasdaq today. Intel and Cisco weren't so lucky though.
5 Top Stock Trades for Thursday: DPZ, NFLX, IBM
Netflix, IBM, Abbott Labs, Domino's Pizza and the IBB ETF were our top stock trades to watch for Thursday, the last trading day this week.
Is AstraZeneca Stock Worth Buying Before Earnings?
AZN stock is great to own, but you should choose your entry points carefully, as AstraZeneca has some short-term risks ahead.
